2. Search Result
Search Result
Results for "

APP processing

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13769A
    TPT-260 Dihydrochloride
    2 Publications Verification

    NSC55712; TPU-260 Dihydrochloride

    		 Drug Derivative Amyloid-β Beta-secretase Cardiovascular Disease Neurological Disease Inflammation/Immunology
    TPT-260 Dihydrochloride (NSC55712), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 Dihydrochloride increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 Dihydrochloride inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 Dihydrochloride improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 Dihydrochloride exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 Dihydrochloride can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease .
    TPT-260 Dihydrochloride
  • HY-114174
    Fmoc-Ala-Glu-Asn-Lys-NH2
    3 Publications Verification

    		 Amyloid-β Neurological Disease
    Fmoc-Ala-Glu-Asn-Lys-NH2 is a selective asparagine endopeptidase (AEP) inhibitor peptide and suppresses amyloid precursor protein (APP) cleavage. AEP, a pH-controlled cysteine proteinase, is activated during ageing and mediates APP proteolytic processing .
    Fmoc-Ala-Glu-Asn-Lys-NH2
  • HY-13769
    TPT-260

    TPU260

    		 Drug Derivative Beta-secretase Amyloid-β Cardiovascular Disease Neurological Disease Inflammation/Immunology
    TPT-260 (TPU260), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease .
    TPT-260
  • HY-P2551
    Biotin-β-Amyloid (17-40)

    		Amyloid-β Neurological Disease
    Biotin-β-Amyloid (17-40) is a N-terminal-labelled biotinylated amyloid-β(1-40) peptide. β-Amyloid (17-40) is a 24-residue fragment of the Aβ protein via post-translational processing of amyloid precursor protein (APP) .
    Biotin-β-Amyloid (17-40)
  • HY-168241
    Flucopride

    		Cholinesterase (ChE) 5-HT Receptor Infection
    Flucopride (Compound 4a) is an AChE inhibitor (IC50: 24 nM), and a partial 5-HT4R agonist (Ki: 9.6 nM for (h)5-HT4R). Flucopride promotes the non-amyloidogenic processing of APP in COS-7 transiently expressing (h)5-HT4R (EC50: 23.0 nM). Flucopride may has good gastrointestinal track (GIT) penetration, and blood-brain barrier (BBB) cross-membrane penetration (PAMPA assay) .
    Flucopride
  • HY-182429
    NB-533

    		Beta-secretase Cathepsin Amyloid-β Neurological Disease
    NB-533 is an orally active and brain-penetrant BACE-1 inhibitor with a human IC50 of 0.002 μM. NB-533 also inhibits human cathepsin D with an IC50 of 0.001 μM. NB-533 inhibits amyloidogenic amyloid precursor protein (APP) processing and reduces Aβ40 release. NB-533 reduces brain levels of APP metabolite C99 and Aβ40 in transgenic mice. NB-533 can be used for the research of Alzheimer’s disease .
    NB-533
  • HY-118972
    TPI-1917-49

    		Amyloid-β Neurological Disease
    TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ). TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase). TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research .
    TPI-1917-49
  • HY-183057
    GRK2 modulator 1

    		G Protein-coupled Receptor Kinase (GRK) HDAC Neurological Disease
    GRK2 modulator 1 is an orally active, brain-penetrant and selective GRK2 modulator. GRK2 modulator 1 enhances the active, non-phosphorylated GRK2 and prevents mitochondrial GRK2 and TOMM6 aggregation. GRK2 modulator 1 enhances the non-amyloidogenic processing of APP and prevent PHF-tau, neurodegeneration, and neuronal loss. GRK2 modulator 1 decreases the senescence marker, UPAR, reduces the Alzheimer disease (AD)-related mortality, and prolongs survival. GRK2 modulator 1 exerts neuroprotection by inhibiting HDAC6, and counteracts age-related cardiac dysfunction. GRK2 modulator 1 can be used for research on AD .
    GRK2 modulator 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: